

### Average Proteinuria Grade Combined SLE Experiments +/- SEM




FIGURE 1

## Dosing Protocol

SLE-5	Treatment, 3x/wk, Subcutaneously	Age (weeks)															
		25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40
A	5 mg/kg Rapamycin (AY-22989-21)	→															
B	200 ug/ms anti-murine B7.1	→															
	200 ug/ms anti-murine B7.2	→															
C	5 mg/kg Rapamycin (AY-22989-21)	→															
	200 ug/ms anti-murine B7.1	→															
	200 ug/ms anti-murine B7.2	→															
D	5 mg/kg Rapamycin (AY-22989-21)	→															
E	5 mg/kg Rapamycin (AY-22989-21)	→															
	200 ug/ms anti-murine B7.1	→															
	200 ug/ms anti-murine B7.2	→															
F	200 ug/ms anti-murine IL-12	→															
G	Vehicle	→															

FIGURE 2

3 of 5

97 JPS-002 SLE-7 Histopathologic Evaluation of NZB x NZW F1 Hybrid Female Mice							
42 weeks of age							
Group	Animal	Spleen	Spleen	Kidney	Kidney	Kidney	
No Therapy		Lymphoid Hyperplasia	Hematopoiesis	Interstitial Inflammation	Glomerulonephritis Cellularity- Membrane Thickness		Tubular Dilatation
	1	-2	-3	+2	-2	+2	+3
	2	+2	+2	+3	-1	+3	+3
	3	+2	+2	+2	-1	+3	+2
	4	+2	+2	+3	-3	+3	+4
	5	+2	+3	+3	-3	+3	+4
	Mean	+1.2	+1.2	+2.6	-2.0	+2.8	+3.2
Rapamycin (Treatment Weeks 29-36)							
	1	+1	+1	(+1)	0	+1	+1
	2	+1	+1	(+1)	0	+1	0
	3	+1	+1	(+2)	0	0	0
	4	+1	+1	0	0	0	0
	5	+1	+1	(+1)	0	0	0
	Mean	+1.0	+1.0	+1.0	0	+0.4	+0.2
<div>Histologic Grades</div> <div> 0 = Normal  1 = Slight  2 = Mild  3 = Moderate  4 = Marked  5 = Severe  ( ) = Focal not Diffuse </div>							
Histopathologic Assessment : Elizabeth Goad, PhD, DVM.							

FIGURE 3

Ag5




FIGURE 4A




FIGURE 4B

A.

### Single Therapeutic Dosing




FIGURE 5A

B.

### Combined Therapeutic Dosing




FIGURE 5B